Pancreas-sparing and superior mesenteric artery first approach in duodenal adenocarcinoma of the fourth portion of duodenum: A case report

Marie-Julie Lardinois*, Nicolas Meurisse
Abdominal and Transplant Surgery department, University of Liège, Belgium

1. Introduction

Peroperative assessment of resectability in pancreas-sparing duodenectomy for distal duodenal (D3-D4) adenocarcinoma is a challenging task for surgeons. Duodenal adenocarcinoma is a rare lesion that represents 0.3% of all malignant tumors of the gastrointestinal tract [1,2]. Surgery is the only chance of cure. The lesion usually occurs in patients older than 65 [1,3]. The third and the fourth portions of the duodenum are frequently involved [1,2,4]. As symptoms are uncommon, the diagnosis is generally delayed [3,4]. The prognosis is very poor, regardless of the stage of the disease. The 5-year survival can be as low as 14% for unresectable lesions but can reach to 75% if a complete resection is carried out [4,5]. Here we report a patient who underwent pancreas-sparing duodenectomy of the third and fourth portions of duodenum for a duodenal adenocarcinoma of the fourth portion of duodenum using the superior mesenteric artery (SMA) first approach. The article has been reported in line with the SCARE criteria [6] and PROCESS criteria [7].

2. Presentation of case

A 68-year-old man who suffered from intermittent abdominal pain, nausea, diarrhea and weight loss of 10 kg for 3 months was hospitalized at our University. A fecal occult blood test and abdominal ultrasound previously requested by a general practitioner were normal. On admission, blood tests were within normal ranges. An abdominal computed tomography with intravenous contrast enhancement was then carried out which revealed a 4 cm lesion located between the third and the fourth portions of the duodenum. There was proximal distention of the duodenum and the stomach (Fig. 1).

Upper gastrointestinal endoscopy and histopathology of the biopsied specimens demonstrated a high grade dysplastic tubulo-villous adenoma with focal development of adenocarcinoma which had invaded the mucosa. The tumor marker carbohydrate antigen 19-9 (CA 19-9) was slightly increased (52.8kU/l, normal range lower than 37 kU/l) whereas the carcinoembryonic antigen (CEA) was within the normal range (2.8 μg/l). 18-FDG PET-CT showed
activities at the last portion of duodenum, in one mesenteric lymph node (Fig. 2), and in two other focal points in the small intestine and the left colon.

Laparotomy was carried out. Resectability was first assessed by the absence of liver metastasis on peroperative ultrasound, followed by exposing completely the third and the fourth parts of the duodenum through a Cattell-Braasch and a Kocher maneuvers. Any SMA involvement was assessed through entire dissection of its proximal part. The serosa of the distal portion of duodenum and the inferior mesenteric vein were found to be invaded. A pancreas-sparing en-bloc resection of a part of the second, the third and fourth portions of duodenum combined with loco-regional lymph node dissection around the portal vein and superior mesenteric artery were performed (Figs. 3-4). A R0 resection were achieved after dividing the first two jejunal arteries. Excision of the lesion was carried out after identification of the major duodenal papilla, which had previously been catheterized by a transcystic drain. The digestive continuity was restored by a side-to-side hand-sewn duodeno-jejunal anastomosis.

Histopathology demonstrated a poorly-differentiated adenocarcinoma with full-thickness invasion and extension beyond the wall with infiltration into the perivisceral fat (Fig. 5). Four of 19 lymph nodes procured were involved by tumor. The resection margins were negative (R0). According to the TNM classification, the adenocarcinoma was pT4N2 Mx.

For the two others FDG uptake lesions shown in the preoperative PET-CT, a grade 1 neuroendocrine tumor invading the submucosal layer of the ileum and a diverticulitis of the left colon were demonstrated.
tumor but lymphomas or sarcomas can also be found [9]. Adenocarcinomas are more common in the duodenum whereas carcinoid tumors are frequently located in the ileum [10]. Of the duodenal adenocarcinomas, 45% arise from the distal portion (third (D3) and fourth parts (D4)), 40% from the second part (D2) and 15% from the first part of duodenum (D1) [1].

The diagnosis is challenging. The patients are usually asymptomatic until the tumor has reached a certain size. Symptoms are then usually non-specific: abdominal pain, weight loss, anemia or intestinal obstruction [2,3,4]. The diagnosis of duodenal adenocarcinoma with gastroscopy is difficult, especially when the tumor occurs at the level of D3 or D4 [4]. For these reasons, delay in diagnosis is frequent. As described by Solej et al., the final diagnosis is obtained from 1.8 to 8 months after onset of symptoms [4]. Video capsule and double-balloon endoscopy are efficient and may diminish the diagnostic delay [3,5,11]. CT scan and 18-FDG-PET-CT are necessary to assess the loco-regional and distant extension of the tumor [4,5,12]. CEA and CA 19-9 have been shown to be prognostic factors for patient survival [5].

Surgical treatment is the only curative option. Surgery starts with assessment of resectability by excluding distant metastasis. The “artery-first” approach of the SMA, as used in pancreatic resection [13,14], is preferred. It allows identifying contra-indications to proceed with surgery early, such as arterial wall infiltration and/or the need to sacrifice too many jejunal arteries which leads to major intestinal resection. Finally, while a duodenopancreactectomy is a prerequisite for proximal lesions (D1 and D2) [15], the need to remove the pancreas in distal duodenal lesions (D3 or D4) depends on whether it is possible to get free resection margins and complete lymph node dissection [15,16] of the mesenteric root. Higher rates of post-operative morbidity and mortality are observed in pancreatic resection when compared with pancreas-sparing duodenectomy [16].

When a complete resection is not feasible, palliative interventions such as bowel bypass or jejunostomy [4] can be considered.

Only a few authors have studied the use of adjuvant radiotherapy or chemotherapy and these authors are not very enthusiastic [5]. The prognosis of a patient with a duodenal adenocarcinoma remains very poor, regardless of the stage of the disease. A 5-year overall survival rate between 23% and 37% has been described in the literature [17,18]. Complete resection increases the 5-year survival from 25% [19] to 75% [20]. Long-term survival is also related to the number of invaded lymph nodes [5]. No link between the type of surgery and long term survival has been described [16].

4. Conclusion

Adenocarcinoma of the distal portion of duodenum is uncommon. The prognosis is bad. The tumor has non-specific symptoms. The diagnosis is difficult and is frequently delayed. The only chance of cure is a R0 resection with complete loco-regional lymphadenectomy of the mesenteric root. The artery-first approach with entire dissection of the SMA is an early key step in deciding whether to proceed further. Pancreas-sparing distal duodenectomy should be considered per-operatively to avoid the pancreatectomy-related morbidity.

Conflict of interest

The authors declare that they do not have conflict of interests.

Sources of funding

We do not have any sources of funding.
Ethical approval

The case report is exempt from ethical approval.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Authors contributions

MJ Lardinois took part of the surgical operation and wrote the article. N Meurisse managed the surgical operation and reviewed the manuscript.

Registration of research studies

This is not a research study.

Guarantor

MJ Lardinois is the guarantor of this work.

References

[1] R. Gore, Small bowel cancer: clinical and pathologic features, Radiol. Clin. North Am. 35 (1997) 351–360.
[2] A. Tocchi, G. Mazzoni, F. Puma, M. Miccini, Adenocarcinoma of the third and fourth portions of the duodenum, Arch. Surg. 138 (2003) 80–85.
[3] F. Paquissi, A. Lima, M. Lopes, F. Dias, Adenocarcinoma of the third and fourth portions of the duodenum: the capsule endoscopy value. World J. Gastroenterol. 21 (2015) 9437–9441.
[4] M. Solej, S. D’Amico, G. Bronzino, M. Ferronato, Primary duodenal adenocarcinoma, Tumori 94 (2008) 779–786.
[5] T. Aparicio, A. Zaanan, M. Svrek, Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment, Dig. Liver Dis. 46 (2014) 97–104.
[6] R.A. Agha, A.J. Fowler, A. Saetta, I. Barai, S. Rajmohan, Orgill DP, for the SCARE group. The SCARE statement: consensus-based surgical case report guidelines, Int. J. Surg. 34 (2016) 180–186.
[7] R.A. Agha, A.J. Fowler, S. Rajmohan, I. Barai, Orgill DP, for the PROCESS Group: preferred reporting of case series in surgery: the PROCESS guidelines, Int. J. Surg. 36 (2018) 319–323.
[8] D. Dindo, N. Demartines, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann. Surg. 240 (2004) 205–213.
[9] A. Johnson, P. Harmy, Primary small bowel malignancies, Am. J. Surg. 51 (1985) 31–36.
[10] J. Cunningham, R. Aleali, M. Aleali, S. Brower, Malignant small bowel neoplasms histopathologic determinants of recurrence and survival, Ann. Surg. 225 (1997) 300–306.
[11] A. Safatle, T. Franzini, R. Kuga, Double-balloon enteroscopy in the diagnosis of an adenocarcinoma of the fourth portion of the duodenum: report of a case, Tumori 94 (2008) 9437–9441.
[12] C. Cronin, J. Scott, Utility of positron emission tomography/CT in the evaluation of small bowel pathology, Br. J. Radiol. 85 (2012) 1211–1221.
[13] J. Wetz, N. Rahbari, The artery-first approach for resection of pancreatic head cancer, J. Am. Coll. Surg. 210 (2010) 1–4.
[14] P. Sanjay, K. Takaori, ‘Artery-first’ approaches to pancreatosuodenectomy, Br. J. Surg. 99 (2012) 1027–1035.
[15] D. Scott-Coombes, Surgical treatment of primary duodenal carcinoma: a personal series, Br. J. Surg. 81 (1994) 1472–1474.
[16] I. Kaklamanos, Extent of resection in the management of duodenal adenocarcinoma, Am. J. Surg. 179 (2000) 37–41.
[17] J. Faivre, A. Trama, R. De Angelis, et al., Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995–2002, Eur. J. Cancer 42 (2012) 1417–1424.
[18] C. Legage, A.M. Bouvier, S. Mainfredi, et al., Incidence and management of primary malignant small bowel cancers: a well-defined French population study, Am. J. Gastroenterol. 101 (2006) 2826–2832.
[19] E. Santoro, M. Sacchi, F. Scutari, F. Carboni, F. Graziano, Primary adenocarcinoma of the duodenum: treatment and survival in 89 patients, Hepatogastroenterology 44 (1997) 1157–1163.
[20] P. Bucher, Gervaz P, Morel P: Long-term results of radical resection for locally advanced duodenal adenocarcinoma, Hepatogastroenterology 52 (2005) 1727–1729.

Open Access
This article is published Open Access at sciencedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.